Pipeline

A powerful approach

We are leveraging the genetic principle of synthetic lethality and the power of our state-of-the-art CRISPR-based target discovery engine to discover and validate multiple novel targets each year. Our growing pipeline consists of programs for genetically defined subsets of cancers with limited treatment options.

Development Pipeline

Program
Patient Selection
Discovery
IND-Enabling
Clinical Trials
Anticipated Milestones
PRMT5 TNG908
MTAP-del cancers
Phase 1/2
Phase 3
Initial clinical data 1H 2023
Phase 1/2
Patients: MTAP-del cancers
Anticipated Milestones: Initial clinical data 1H 2023
Development Pathway

Our Phase 1/2 first-in-human trial to evaluate TNG908 in patients with MTAP-deleted tumors is being conducted in two parts. The dose escalation phase will evaluate safety, efficacy, pharmacokinetics and pharmacodynamics in patients with locally advanced or metastatic cancer of any histology (with the exception of central nervous system tumors) with an MTAP deletion. After determining the optimally-effective dose for TNG908, we will further evaluate safety and efficacy in multiple tumor types in specific cohorts, including malignant peripheral nerve sheath tumor (MPNST – a rare sarcoma), non-small cell lung cancer, mesothelioma, cholangiocarcinoma and glioblastoma.  In parallel, we will enroll a histology-agnostic arm to evaluate all other tumor types with MTAP deletion. Given that MTAP deletion occurs in approximately 10-15% of human cancers, we may open other histology-specific arms based on activity observed in the trial.

The FDA cleared the Investigational New Drug (IND) application for TNG908 in January 2022 and granted Fast Track Designation in February 2022.  The Phase 1/2 clinical trial is now open for enrollment. We expect to have initial safety and efficacy available in the first half of 2023.

Learn more about our trial here →

PRMT5 TNG462
MTAP-del cancers
IND filing 1H 2023
IND-Enabling
Patients: MTAP-del cancers
Anticipated Milestones: IND filing 1H 2023
Development Pathway

The clinical development path for TNG462 is expected to be similar to TNG908, evaluating safety and efficacy in multiple tumor types in a Phase 1/2 clinical trial. Glioblastoma will be excluded from the Phase 1/2 trial as TNG462 does not cross the blood-brain barrier in preclinical models. We expect to file an IND for TNG462 in the first half of 2023 and are planning to fully evaluate both TNG908 and TNG462 in clinical trials.

TARGET 3* TNG260
STK11-mut cancers
IND filing 2023
IND-Enabling
Patients: STK11-mut cancers
Anticipated Milestones: IND filing 2023
Development Pathway

The TNG260 clinical development plan will be among the first to combine the power of genetic patient selection and immunotherapy, evaluating patients with STK11 mutant cancers in a trial combining TNG260 and a checkpoint inhibitor. We plan to file an IND for TNG260 in 2023.

USP1
BRCA 1/2-mut cancers
Development candidate 2H 2022
Discovery
Patients: BRCA 1/2-mut cancers
Anticipated Milestones: Development candidate 2H 2022
Development Pathway

Our preclinical work provides the basis for the future clinical trials of a USP1 inhibitor both as a single agent and in combination with PARP inhibitors in BRCA1/2-mutant cancers. We plan to evaluate USP1 as a single agent in patients with primary and secondary resistance to PARP inhibitors and in combination with PARP inhibitors in PARP-inhibitor naïve patients. Patient selection markers are being evaluated for BRCA1 WT populations, particularly in a subset of non-small cell lung cancer cell lines sensitive to USP1 inhibition. We plan to declare a development candidate in the second half of 2022 and file an IND for this program in 2023.

Multiple synthetic lethal targets
Tumor suppressor gene loss
Discovery

Gilead options and licensed targets not listed – learn more about our partnership below
*Wholly-owned immune evasion program

Partnerships

Our global strategic collaboration with Gilead Sciences is focused on the discovery, development and commercialization of a pipeline of innovative targeted immune evasion therapies for patients with cancer. We are responsible for discovering and validating targets and for advancing select programs through clinical proof-of-concept. Gilead has options to worldwide rights on up to 15 of those targets. We retain the option to co-develop and co-promote the lead products for up to five of those programs in the U.S. with Gilead.

The collaboration, which was originally signed in 2018 and expanded in 2020, does not include our three lead programs. We retain all rights to those programs, along with the right to targets we have identified outside of the immune evasion space. We are committed to advancing the programs in our wholly owned pipeline into the clinic and beyond, as part of our mission to deliver the next generation of transformational targeted therapies to patients in need.

Tango Therapeutics Gilead

The Gilead logo is a trademark of Gilead Sciences, Inc.

We aim to become a fully-integrated biotechnology company bringing transformative medicines to people with cancer. We believe strategic collaborations with pharma and other biotech companies can help us achieve this goal and deliver more novel cancer drug targets and medicines to patients. Please reach out if you are interested in exploring ways to work together: bd@tangotx.com.

Learn more about the culture of innovation at Tango.Learn more about the culture of innovation at Tango.